During the treatment period with TRK-950, the tumor marker CA19-9 ranged from 4 to 27 U/mL, and carcinoembryonic antigen ranged from 1.6 to 3.4 ng/mL, with both marker values remaining within the reference range (Supplementary Table S4). Here, CEACAM5 is linked to neoplasm.